Can testosterone be used to treat hypoactive sexual desire disorder in adult women, and what are the recommended evaluation, dosing, and monitoring protocols?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testosterone Therapy for Women with Hypoactive Sexual Desire Disorder

Primary Recommendation

Transdermal testosterone (1% gel, 5g applied twice weekly) can be considered for postmenopausal women with hypoactive sexual desire disorder (HSDD) who have failed non-hormonal interventions, but it is not FDA-approved for this indication and should be used with caution given limited long-term safety data. 1

Patient Selection Criteria

Who May Benefit

  • Postmenopausal women (natural or surgical menopause) with distressing low sexual desire that causes personal distress 1, 2
  • Women who have adequate circulating estrogen levels, as testosterone may not be effective without sufficient estrogen 1
  • Women who have failed first-line non-hormonal therapies including cognitive-behavioral therapy, pelvic floor physical therapy, and vaginal moisturizers 1

Absolute Contraindications

  • Current or history of breast cancer or other hormone-dependent malignancies 1, 3
  • Pregnancy or breastfeeding 1
  • Women attempting conception, as testosterone suppresses ovarian function 1

Treatment Protocol

Dosing and Administration

  • Transdermal testosterone 1% gel, 5g applied twice weekly to dry, intact skin of the abdomen, back, upper thighs, or upper arms 1
  • Target testosterone levels in the mid-range of normal female values (not male reference ranges of 500-600 ng/dL) 1
  • The testosterone patch (300 mcg/day) has also been studied and shown efficacy, though not FDA-approved 4, 5

Expected Outcomes

  • Modest benefit: approximately 1 additional satisfying sexual episode every 2 months compared to placebo 1
  • Improvements in sexual desire, arousal, frequency of sexual activity, and reduction in personal distress 4, 5
  • Benefits typically emerge within 3-6 weeks of treatment initiation 6

The effect size is small but statistically significant—clinicians must set realistic expectations with patients that testosterone is not a dramatic solution. 1, 2

Monitoring Requirements

Initial Phase (First Year)

  • Every 3 months: measure total and free testosterone (can be drawn at any time; peak occurs 6-8 hours post-application), complete blood count, lipid profile, and liver function tests 1, 6
  • Assess for virilization symptoms: acne, hirsutism, voice deepening, clitoromegaly 6, 5

Efficacy Assessment

  • Reassess clinical response at 3-6 months; if no improvement in sexual desire or function, discontinue therapy 1
  • Limit treatment duration to 24 months maximum due to lack of long-term safety data 1

Safety Considerations

Common Side Effects

  • Mild facial acne (typically resolves within 2 months of discontinuation) 6
  • Increased hair growth 5
  • Application site reactions 4

Serious Concerns

  • Cardiovascular effects: interim data suggest low rates of cardiovascular events, but long-term safety is not established 5
  • Breast cancer risk: not conclusively established, but women with breast cancer history should avoid testosterone 1, 5
  • Endometrial effects: available data are reassuring but not definitive 5

Dose-Response Relationship

Women exhibit a bell-shaped dose-response curve for testosterone—exceeding moderate doses does not enhance benefits and may cause aggression, virilization, and other side effects that counteract sexual benefits. 7 This is fundamentally different from men, who show a linear dose-response relationship.

Alternative Treatment Options

FDA-Approved Alternatives (Premenopausal Women)

  • Flibanserin 100mg at bedtime daily is the first-line pharmacologic option for premenopausal women with HSDD 1, 3
  • Bremelanotide (injectable) is another FDA-approved option for premenopausal HSDD 3

Other Options

  • Intravaginal DHEA (prasterone) may improve sexual function in women with concurrent dyspareunia 3
  • Vaginal testosterone cream may be a safer alternative to systemic administration, particularly for cancer survivors 3
  • Bupropion or buspirone have limited data but may be considered as second-line options 1

Clinical Algorithm

  1. Confirm diagnosis: postmenopausal woman with distressing low sexual desire (HSDD) causing personal distress 1, 2

  2. Rule out contraindications: breast cancer history, pregnancy, breastfeeding, attempting conception 1

  3. Ensure adequate estrogen: testosterone may not work without sufficient circulating estrogen 1

  4. Trial non-hormonal interventions first: cognitive-behavioral therapy, pelvic floor therapy, vaginal moisturizers 1

  5. If non-hormonal therapies fail, consider transdermal testosterone 1% gel 5g twice weekly 1

  6. Monitor every 3 months during the first year: testosterone levels, CBC, lipids, liver function, virilization symptoms 1, 6

  7. Reassess efficacy at 3-6 months; discontinue if no improvement 1

  8. Limit treatment to 24 months maximum due to lack of long-term safety data 1

Critical Pitfalls to Avoid

  • Do not prescribe testosterone as first-line therapy—non-hormonal interventions should be attempted first 1
  • Do not use testosterone in women with breast cancer history—safety is not established 1, 3
  • Do not exceed moderate doses—higher doses do not improve outcomes and may cause harm due to the bell-shaped dose-response curve in women 7
  • Do not target male testosterone ranges (500-600 ng/dL)—women require mid-range female values 1
  • Do not continue therapy beyond 24 months—long-term safety data are lacking 1
  • Do not prescribe without monitoring—every 3-month follow-up is essential during the first year 1, 6

Key Differences from Male Testosterone Therapy

  • Women show a bell-shaped (curvilinear) dose-response, whereas men show a linear relationship 7
  • Target testosterone levels are mid-range female values, not male ranges 1
  • Efficacy is modest (1 additional satisfying episode every 2 months), whereas men with hypogonadism show more robust improvements in sexual function 1, 2
  • Long-term safety is not established in women, whereas men have more extensive safety data 1, 2

References

1
Guideline

Testosterona para Disfunção Sexual Hipoativa em Mulheres

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Injectable Testosterone Dosing for Postmenopausal Women with HSDD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4
Research

Testosterone treatment of HSDD in naturally menopausal women: the ADORE study.

Climacteric : the journal of the International Menopause Society, 2010

Related Questions

What are the recommendations and dosing (posology) for prescribing testosterone for Hypoactive Sexual Desire Disorder (HSDD) in women?
In a cisgender woman treated for hypoactive sexual desire or mild androgen deficiency, does transdermal testosterone cream produce a higher conversion to dihydrotestosterone than intramuscular testosterone injections?
Can a post‑menopausal woman with documented low serum testosterone and hypoactive sexual desire refractory to counseling be treated with subcutaneous testosterone injection?
What is the recommended starting weekly intramuscular testosterone dose and titration schedule for adult women with hypoactive sexual desire disorder?
What is the recommended starting dose, titration schedule, monitoring parameters, and contraindications for 0.5% testosterone cream in an adult woman being treated for hypoactive sexual desire disorder or documented low serum testosterone?
What are the recommended loading and maintenance doses of fluconazole and voriconazole for invasive candidiasis and invasive aspergillosis, and how should these doses be adjusted in patients with impaired renal function (creatinine clearance ≤50 mL/min) or hepatic impairment (Child‑Pugh A‑C)?
What are the side effects of Nurtec (rimegepant) when used for migraine in a perimenopausal woman?
What is the most effective first‑line treatment for common cutaneous warts?
Which medications are contraindicated in patients with glaucoma?
Why would a 60‑year‑old man with symptomatic hypogonadism need to target a serum testosterone level of approximately 850 ng/dL?
In a 60-year-old man with symptomatic hypogonadism and a history of mood disorders, is it appropriate to target a serum total testosterone level of approximately 850 ng/dL with testosterone replacement therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question